FY2027 EPS Estimates for Novartis Cut by Zacks Research

Novartis AG (NYSE:NVS) – Investment analysts at Zacks Research lowered their FY2027 earnings per share estimates for Novartis in a note issued to investors on Friday, May 8th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $9.73 for the year, down from their prior forecast of $9.79. The consensus estimate for Novartis’ current full-year earnings is $8.85 per share.

NVS has been the topic of a number of other reports. Argus upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Wednesday, March 11th. Weiss Ratings lowered Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Wall Street Zen cut Novartis from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. TD Cowen reissued a “hold” rating on shares of Novartis in a research report on Tuesday, February 17th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a research note on Thursday, February 12th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $141.20.

Novartis Stock Performance

Shares of NVS opened at $145.11 on Tuesday. The firm has a market cap of $276.89 billion, a P/E ratio of 20.79, a PEG ratio of 2.56 and a beta of 0.46. Novartis has a twelve month low of $104.93 and a twelve month high of $170.46. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85. The firm’s 50 day moving average price is $152.36 and its two-hundred day moving average price is $144.51.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.11 by ($0.12). Novartis had a net margin of 24.87% and a return on equity of 38.82%. The business had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. During the same quarter in the prior year, the firm posted $2.28 earnings per share. Novartis’s revenue for the quarter was down .9% compared to the same quarter last year.

Institutional Trading of Novartis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC increased its position in shares of Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after purchasing an additional 2,666 shares during the last quarter. AQR Capital Management LLC raised its position in Novartis by 102.8% during the first quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock worth $2,516,000 after acquiring an additional 11,444 shares in the last quarter. Empowered Funds LLC acquired a new stake in Novartis in the first quarter valued at $1,764,000. Sivia Capital Partners LLC grew its position in shares of Novartis by 48.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock valued at $963,000 after acquiring an additional 2,581 shares during the period. Finally, Schnieders Capital Management LLC. bought a new position in shares of Novartis in the 2nd quarter valued at about $202,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.